These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8405032)

  • 21. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
    Dalén P; Dahl M; Andersson K; Bertilsson L
    Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients.
    Cerqueira PM; Cesarino EJ; Mateus FH; Mere Y; Santos SR; Lanchote VL
    Chirality; 1999; 11(7):591-7. PubMed ID: 10423287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism.
    Muralidharan G; Midha KK; McKay G; Hawes EM; Inaba T
    Xenobiotica; 1989 Feb; 19(2):189-97. PubMed ID: 2786289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers.
    Lennard MS; Tucker GT; Silas JH; Freestone S; Ramsay LE; Woods HF
    Clin Pharmacol Ther; 1983 Dec; 34(6):732-7. PubMed ID: 6641087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
    Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
    Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.
    Mikus G; Bochner F; Eichelbaum M; Horak P; Somogyi AA; Spector S
    J Pharmacol Exp Ther; 1994 Feb; 268(2):546-51. PubMed ID: 8113966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.
    Bozkurt A; Basçi NE; Işimer A; Sayal A; Kayaalp SO
    Eur J Drug Metab Pharmacokinet; 1996; 21(4):309-14. PubMed ID: 9074895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
    Herchuelz A; Gangji D; Derenne F; Jeanniot JP; Douchamps J
    Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
    Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
    Lennard MS; Silas JH; Freestone S; Trevethick J
    Br J Clin Pharmacol; 1982 Aug; 14(2):301-3. PubMed ID: 6125207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.
    Hayhurst GP; Harlow J; Chowdry J; Gross E; Hilton E; Lennard MS; Tucker GT; Ellis SW
    Biochem J; 2001 Apr; 355(Pt 2):373-9. PubMed ID: 11284724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine.
    Ashforth EI; Palmer JL; Bye A; Bedding A
    Br J Clin Pharmacol; 1994 Apr; 37(4):389-91. PubMed ID: 8018461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.
    Jonkers RE; Koopmans RP; Portier EJ; van Boxtel CJ
    J Pharmacol Exp Ther; 1991 Mar; 256(3):959-66. PubMed ID: 1848636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polymorphic metabolism of metoprolol: clinical studies.
    Silas JH; McGourty JC; Lennard MS; Tucker GT; Woods HF
    Eur J Clin Pharmacol; 1985; 28 Suppl():85-8. PubMed ID: 4054194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing.
    Freestone S; Silas JH; Lennard MS; Ramsay LE
    Br J Clin Pharmacol; 1982 Nov; 14(5):713-8. PubMed ID: 7138751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metoprolol alpha-hydroxylation polymorphism in the San Bushmen of southern Africa.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1989 Jan; 8(1):39-43. PubMed ID: 2714809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.
    Brynne N; Böttiger Y; Hallén B; Bertilsson L
    Br J Clin Pharmacol; 1999 Feb; 47(2):145-50. PubMed ID: 10190648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Debrisoquine oxidation polymorphism in a Tasmanian population.
    Veronese ME; McLean S
    Eur J Clin Pharmacol; 1991; 40(5):529-32. PubMed ID: 1884730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.